Datapoint: BMS Settles HIV Antitrust Suit

Bristol Myers Squibb could pay up to $11 million to settle a lawsuit brought by HIV activists, which claimed the company used anticompetitive practices to block generic competition to its HIV drugs, including Evotaz. Evotaz is a cocktail therapy, made in partnership between BMS and Gilead Sciences. Gilead and Johnson & Johnson are set to move forward with a trial, beginning sometime in 2023. Under the pharmacy benefit, 92% of all insured lives have covered or better access to Evotaz as an HIV antiviral. 47.3% of lives have preferred access to Evotaz, without utilization management restrictions.

SOURCE: MMIT Analytics, as of 4/15/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 6

Datapoint: Moda Health to Expand to Idaho

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 5

Datapoint: North Carolina Delays Launch of New Medicaid MCOs

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 4

Datapoint: FDA Approves Avastin Biosimilar

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today